ASX Share rice
Thu 13 May 2021 - 12:11:pm (Sydney)

CP1 Share Price

CANNPAL ANIMAL THERAPEUTICS LIMITEDCP1Pharmaceuticals, Biotechnology & Life Sciences

CP1 Company Information


CannPal Animal Therapeutics Limited




Drug Manufacturers-Specialty & Generic

GIC Industry:


GIC Sub Industry:



45a Bay Street Double Bay NSW Australia 2028


61 2 6108 3622

Founder, MD & Director:

Mr. Layton Patrick Mills

Head of Clinical Devel. and R&D:

Dr. Margaret Curtis

CFO & Company Sec.:

Mr. Baden Maxwell Bowen

Chief Scientific Officer & Member of Advisory Board:

Dr. Rayson Tan

Company Overview:

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia. As of March 11, 2021, CannPal Animal Therapeutics Limited operates as a subsidiary of AusCann Group Holdings Ltd.

CP1 Share Price Information

Shares Issued:


Dividend Yield:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CP1 CashFlow Statement

CashFlow Date:


Change To Liabilities:


Net Income:


Total Cash From Operating Activities:


Capital Expenditures:


CP1 Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Total Revenue:


CP1 Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Retained Earnings:




Total Current Liabilities:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


CP1 Share Price History

CP1 News

08 Nov, 2020
The CEO of CannPal Animal Therapeutics Limited (ASX:CP1) is Layton Mills, and this article examines the executive's...
21 Jul, 2020
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") has released results from its safety and efficacy study for DermaCannĀ®, an oral nutraceutical developed for healthy skin and immune function for dogs.